isobavachalcone and Disease-Models--Animal

Acute myeloid leukemia is a disorder characterized by abnormal differentiation of myeloid cells and a clonal proliferation derived from primitive hematopoietic stem cells. Interventions that overcome myeloid differentiation have been shown to be a promising therapeutic strategy for acute myeloid leukemia. In this study, we demonstrate that CRISPR/Cas9-mediated knockout of dihydroorotate dehydrogenase leads to apoptosis and normal differentiation of acute myeloid leukemia cells, indicating that dihydroorotate dehydrogenase is a potential differentiation regulator and a therapeutic target in acute myeloid leukemia. By screening a library of natural products, we identified a novel dihydroorotate dehydrogenase inhibitor, isobavachalcone, derived from the traditional Chinese medicine

Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chalcones; Dihydroorotate Dehydrogenase; Disease Models, Animal; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Gene Expression; Gene Knockdown Techniques; Humans; Leukemia, Myeloid, Acute; Mice; Models, Molecular; Molecular Structure; Neoplastic Stem Cells; Oxidoreductases Acting on CH-CH Group Donors; Prognosis; RNA Interference; Structure-Activity Relationship; Xenograft Model Antitumor Assays

Topics: Administration, Oral; Animals; Carbon Tetrachloride; Cell Survival; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Dose-Response Relationship, Drug; Glycyrrhiza; Hep G2 Cells; Humans; Male; Mice; Mice, Inbred ICR; Molecular Structure; NF-E2-Related Factor 2; Plant Extracts; Plant Roots; Rats; Rats, Sprague-Dawley

Parkinson's disease (PD) is a complex multi-system and age-related neurodegenerative disorder. The intervention targeting neuroinflammation in PD patients is one effective strategy to slow down or inhibit disease progression. Microglia-mediated inflammatory response plays an important role in Parkinson's, Alzheimer's and other cerebral diseases. Isobavachalcone is a main component of Chinese herb medicine Psoralea corylifolia, which function includes immunoregulation, anti-oxidation and the regulation of β-amyloid (Aβ42) deposited in hippocampus in Alzheimer's patients. Whether it has the therapeutic effect on Parkinson's disease, however, is unclear. In this study, we found that isobavachalcone could effectively remit Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), prolong the residence time of mice on Rota-rod and alleviate the neuronal necrosis. It also inhibited the over-activation of microglia, and decreased the expression of IL-6 and IL-1β in the brain of PD mice. In vitro, isobavachalcone could inhibit nuclear factor-kappaB (NF-κB) pathway through inhibiting the LPS-induced transfer of NF-κB subunit from cytoplasm to nucleus in BV-2 cells. Isobavachalcone decreased the LPS-induced oxidative stress and the expression of inflammatory cytokines, and provided a neuroprotective effect by antagonizing microglia-mediated inflammation. Our results indicated that isobavachalcone may be a candidated drug against Parkinson's disease with great clinical potential.

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biomarkers; Cell Line; Chalcones; Disease Models, Animal; Inflammation Mediators; Interleukin-6; Male; Mice; Microglia; Motor Activity; Neurons; Neuroprotective Agents; NF-kappa B; Nitric Oxide Synthase Type II; Parkinson Disease; Signal Transduction